SCHEMBL731092

SCHEMBL731092

COc1c[c]cc(-c2ccc3[nH]ccc3c2)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 2/20 0.49
MEN1 O00255 3/20 0.45
KMT2A Q03164 3/20 0.45
POLB P06746 1/20 0.45
MAPK1 P28482 1/20 0.45
CHRNB4 P30926 2/20 0.43
CHRNA3 P32297 2/20 0.43
CHRNA7 P36544 2/20 0.43
CHRNA10 Q9GZZ6 2/20 0.43
CHRNA9 Q9UGM1 2/20 0.43
MAOA P21397 1/20 0.43
MAOB P27338 1/20 0.43
CHRNB2 P17787 1/20 0.42
CHRNA4 P43681 1/20 0.42
CA12 O43570 1/20 0.42
CA1 P00915 1/20 0.42
CA2 P00918 1/20 0.42
CA9 Q16790 1/20 0.42
PTGS2 P35354 1/20 0.42
HCRTR1 O43613 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7089083 0.81 NPC1 (0.62) NPC1MEN1KMT2APOLBMAPK1
SCHEMBL31504069 0.80 NPC1 (0.62) NPC1MEN1KMT2APOLBMAPK1
SCHEMBL2183291 0.80 NPC1 (0.53) NPC1CHRNB4CHRNA3CHRNA7CHRNA10
SCHEMBL731067 0.78 PRKCQ (0.52) NPC1MEN1KMT2AHCRTR1CASP3
SCHEMBL31317869 0.77 CYP11B1 (0.63) NPC1DYRK3CCNT1CDK9CDK5
SCHEMBL733118 0.75 DYRK3 (0.48) NPC1MEN1KMT2AHCRTR1CASP3
SCHEMBL5850255 0.75 NPC1 (0.79) NPC1CA12CA1CA2CA9
SCHEMBL74720 0.73 MEN1 (0.71) NPC1MEN1KMT2APOLBMAPK1
SCHEMBL29992449 0.73 MEN1 (0.71) NPC1MEN1KMT2APOLBMAPK1
SCHEMBL729645 0.73 RXRA (0.54) NPC1MAOAMAOBPTGS2ABCB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2120569-B1 SPIROCHROMANON DERIVATIVES MERCK SHARP & DOHME (US) 2013-08-14 EP disclosed
US-8138197-B2 Spirochromanon derivatives MSD K.K. (JP) 2012-03-20 US disclosed
EP-2120569-A2 SPIROCHROMANON DERIVATIVES Merck & Co., Inc. (US) 2009-11-25 EP disclosed
US-20090270436-A1 SPIROCHROMANON DERIVATIVES MERCK SHARP & DOHME LLC 2009-10-29 US disclosed
WO-2008088692-A2 SPIROCHROMANON DERIVATIVES MERCK & CO., INC. (US) 2008-07-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090270436-A1 SPIROCHROMANON DERIVATIVES AKR1C3, CBR3, AKR1C4 NPC1 2438/4885MEN1 2567/4885KMT2A 3686/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.